BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Gloria Biosciences' Zimberelimab Approved in China for Recurrent Cervical Cancer

Guangzhou Gloria Biosciences ("GloriaBio"), a commercial stage biopharmaceutical company focusing on the discovery, development and commercialization of bi...

September 07, 2023 | News

IBT and ATLATL Join Forces to Tackle Challenges in Brain Health

Starting out of China, IBT Global is a rising player in Digital Therapeutics (DTx) with an experienced cross-functional team operating at the intersection ...

September 05, 2023 | News

China-Africa medical cooperation broadens under BRI

From there, he can admire the breathtaking views of the sleek, curved structure and the intricately layered sunshade components, showcasing the marvels of ...

September 04, 2023 | News

ABM Therapeutics Initiates Phase I Study of ABM-1310 in BRAF V600 Brain Tumors

ABM-1310, the company's proprietary clinical candidate developed as a next-generation BRAF inhibitor and demonstrated superior properties in pre-clinical a...

September 04, 2023 | News

Innovac Therapeutics Secures $18M Pre-A Funding for Lead Program Development

Innovac Therapeutics, an mRNA therapeutics company, announced the completion of an $18 million Series Pre-A financing. The financ...

September 04, 2023 | News

Biocytogen Creates Divisions to Separate Preclinical Models and Antibody R&D

Biocytogen’s preclinical platforms include custom gene-editing services, generation of off-the-shelf humanized and/or immunodeficient animal and cell...

August 31, 2023 | News

Mindray Elevates Patient Safety and Efficiency with Upgraded A Series Anaesthesia Systems

"The demand for more diversified and higher- quality anaesthesia practices are ever-growing. In response to this need, Mindray has developed the A7 and A5 ...

August 31, 2023 | News

Epigenic Therapeutics Raises $32M for Breakthrough Epigenome Medicine Development

This round of financing will support the preclinical development and early clinical validation of two leading programs, discovery of future pipelines, expa...

August 30, 2023 | News

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

The study of savolitinib is a single-arm, multi-center, open-label, Phase II registration study to evaluate the efficacy, safety and tolerability of savoli...

August 29, 2023 | News

Akeso's Ebdarokimab NDA Accepted by China NMPA for Psoriasis

Ebdarokimab is Akeso's 6th self-developed innovative drug that has been successfully approved for marketing/NDA submitted, the first patented domestic inno...

August 25, 2023 | News

Sanyou and Sinorda Partner for Innovative Drug Research

According to the cooperation agreement, leveraging Sanyou's world-leading core technology platform for integrated R&D and preclinical development of in...

August 23, 2023 | News

Lynk Pharma's LNK01001 Shows Positive Results in Ankylosing Spondylitis Phase II Trial

The study, led by Professor Xiaofeng Zeng, the director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital and ...

August 23, 2023 | News

magAssist's NyokAssist™️ granted Designation by the FDA as a Breakthrough Device

Interventional VADs have been proven as an effective clinical therapy to provide mechanical circulatory support for high-risk percutaneous interventions, t...

August 22, 2023 | News

Everest Medicines' Partner Calliditas Therapeutics Gets FDA Priority Review for Nefecon® in IgA Nephropathy

"We congratulate our partner Calliditas for being granted priority review by the FDA for full approval and taking a step closer to offering this first-in-d...

August 22, 2023 | Regulatory

Stay Connected